Premium
Plasma exchange and immunoadsorption effectively remove antiphospholipid antibodies in pregnant patients with antiphospholipid syndrome
Author(s) -
Bontadi Agnese,
Ruffatti Amelia,
Marson Piero,
Tison Tiziana,
Tonello Marta,
Hoxha Ariela,
De Silvestro Giustina,
Punzi Leonardo
Publication year - 2012
Publication title -
journal of clinical apheresis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.697
H-Index - 46
eISSN - 1098-1101
pISSN - 0733-2459
DOI - 10.1002/jca.21229
Subject(s) - medicine , immunoadsorption , antiphospholipid syndrome , antibody , titer , apheresis , gastroenterology , pregnancy , aspirin , immunology , platelet , biology , genetics
Abstract Conventional therapy with aspirin and/or heparin is at times incapable of preventing complications in high risk pregnancies of patients with antiphospholipid syndrome (APS). In those cases, a so‐called second‐line treatment protocol is used in addition to conventional therapy strategies. This manuscript is a report on three APS pregnant patients who were successfully treated with plasma exchange (PE) (two cases) or with immunoadsorption (IA) (one case) as a second‐line treatment strategy. The efficacy of these procedures in removing anticardiolipin (aCL) and anti‐β 2 glycoprotein I (aβ 2 GPI) antibodies from blood was evaluated. Serum samples were collected before and after 87 apheretic treatment sessions. Serum IgG/M aCL and IgG/M aβ 2 GPI antibodies were determined using an “in‐house” enzyme‐linked immunosorbent assay and showed that all three patients had medium/high IgG aCL and aβ 2 GPI titers. All three women had a successful pregnancy. A significant decrease in IgG aCL ( P = 0.0001) and aβ 2 GPI ( P = 0.0001) antibody titers was observed after PE and IA sessions. There was moreover a significant, steady fall in serum IgG aCL pretreatment levels during the course of all three pregnancies ( P = 0.0001, P = 0.0001, P = 0.001). The fall in IgG aβ 2 GPI was significant in two of the patients ( P = 0.0001, P = 0.0001) both with high antibody titers, but not in one with medium antibody titers, who was treated with PE ( P = 0.17). J. Clin. Apheresis 2012. © 2012 Wiley Periodicals, Inc.